How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

10,883 results for

General Medical Books

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. 2018 Book List: A (non-medical) year in review

2018 Book List: A (non-medical) year in review 2018 Book List: A (non-medical) year in review - First10EM Search 2018 Book List: A (non-medical) year in review by | Published - Updated | I tend to read a lot. In previous years, one of the things I have found frustrating is forgetting which books I have already read when when hunting for my next read (especially with long series or authors with a huge number of titles). Therefore, this year I decided to keep track of the books I read. Looking (...) back over the list, and considering how much I like to get book recommendations, I thought others might be interested in my biased and totally unprofessional opinions. It also seems like a nice non-medical year in review type exercise. So I am posting it here. Feel free to ignore. I am am sure to be back sometime soon with some resuscitation or evidence based nerdiness. Wishing you all a great New Year… I have included links to all of these books. These are Amazon affiliate links. That means

2018 First10EM

22. Common clinical conditions in aged care (Silver Book)

Common clinical conditions in aged care (Silver Book) RACGP - Silver Book - Part A Search Become a student member today for free and be part of the RACGP community A career in general practice Starting the GP journey Enrolments for the 2019.1 OSCE FRACGP exams closing 29 March 2019 Fellowship FRACGP exams Research Practice Experience Program is a self-directed education program designed to support non vocationally registered doctors on their pathway to RACGP Fellowship Fellowship International (...) for educators Regional Training The Red Book provides the general practice team with guidance on opportunistic and proactive preventive care Guidelines by topic Key RACGP guidelines Handbook of Non-Drug Interventions (HANDI) Send a request for information, a loan, literature search, journal article, book chapter and one-on-one remote training sessions Library services eBooks Journals Databases and resources Subject portals Download the Standards for general practice (5th edition) - a benchmark for quality

2019 The Royal Australian College of General Practitioners

23. One of the Great Books of Emergency Medicine Just Published: Extraordinary Cases in Emergency Medicine

or opinions expressed herein do not necessarily reflect the views or opinions of Hennepin County Medical Center. As of March 10, 2018, I've decided to run ads here. All ad revenue will go to my ECG research projects. We need funding. Up until now, my wife and I have funded the PERFECT (Paced ECG Requiring Fast Emergent Coronary Therapy) study by making her the full time coordinator without pay. Dr. Smith's Book Recommended Resources More basic books for the less advanced learner: Comments not appropriate (...) One of the Great Books of Emergency Medicine Just Published: Extraordinary Cases in Emergency Medicine Dr. Smith's ECG Blog: One of the Great Books of Emergency Medicine Just Published: Extraordinary Cases in Emergency Medicine Tuesday, January 8, 2019 Doug Brunette is one of the finest Emergency Physicians, if not the finest, whom I have ever known. He was one of the early Hennepin greats, and one of my first and best teachers. He has always been passionate about teaching and practicing

2019 Dr Smith's ECG Blog

24. Effectiveness of Revised Pharmacology Record Books as a Teaching-Learning Method for Second Year Medical Students (PubMed)

Effectiveness of Revised Pharmacology Record Books as a Teaching-Learning Method for Second Year Medical Students The goal of teaching medical undergraduates Pharmacology is to form a sound foundation of therapeutics. The pharmacology record books are maintained as a part of the curriculum. The purpose of this study was to obtain feedback of the medical students about the new record adopted in the institution after major revision.This was a questionnaire based study done in a Government Medical (...) College of Kerala in February 2013. The data was analysed using SPSS. The feedback on clinical pharmacology exercises was given positive and negative scores.Majority (64.5%) opined that the content in pharmacology record was good. A total of 78.1% completed the record during discussions in practical classes. Majority wrote the records for understanding pharmacology. For 79.8% General Pharmacology exercises were most relevant, 33.8% considered Clinical Pharmacology exercises to be the most thought

Full Text available with Trip Pro

2016 Journal of clinical and diagnostic research : JCDR

25. Atezolizumab (non-small cell lung cancer) ? Benefit assessment according to §35a Social Code Book V

Atezolizumab (non-small cell lung cancer) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Atezolizumab (nicht kleinzelliges Lungenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 December 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A17-50 Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-50 Version 1.0 Atezolizumab (non-small cell lung cancer) 27 December 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V Commissioning agency

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

26. Perampanel (epilepsy) - Benefit assessment according to §35a Social Code Book (SGB) V

ACT a 1 Adjunctive therapy for primary generalized tonic- clonic seizures in adults and adolescents aged 12 years and older with idiopathic generalized epilepsy an individual antiepileptic adjunctive therapy, if medically indicated and if no pharmacoresistance/intolerance and contraindications are known yet, with one of the following drugs: lamotrigine, levetiracetam, valproic acid b , topiramate, clobazam Treatment is to be chosen by the doctor depending on the basic and prior therapy/therapies (...) to 3 different antiepileptic drugs; reportedly, they had at least 3 primary generalized tonic-clonic seizures during the 8 weeks before randomization. They were administered either perampanel or placebo as study medication in addition to their ongoing antiepileptic basic therapy. Thereby, perampanel was administered as maintenance dose of Extract of dossier assessment A17-61 Version 1.0 Perampanel (epilepsy) 26 February 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - 3 - 8 mg/day

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

27. Darunavir-cobicistat-emtricitabine-tenofovir alafenamide (HIV infection) - Benefit assessment according to §35a Social Code Book V

Darunavir-cobicistat-emtricitabine-tenofovir alafenamide (HIV infection) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.7 of the dossier assessment Darunavir/Cobicistat/Emtricitabine/Tenofoviralafenamid (HIV-Infektion) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 22 December 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely (...) authoritative and legally binding. IQWiG Reports – Commission No. A17-48 Darunavir/cobicistat/ emtricitabine/tenofovir alafenamide (HIV infection) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-48 Version 1.0 Darunavir/cobicistat/ emtricitabine/tenofovir alafenamide (HIV infection) 22 December 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Darunavir

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

28. Tivozanib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

Tivozanib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Tivozanib (Nierenzellkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 29 January 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-58 Tivozanib (...) (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-58 Version 1.0 Tivozanib (renal cell carcinoma) 29 January 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Tivozanib (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 2

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

29. Brodalumab (plaque psoriasis) ? Benefit assessment according to §35a Social Code Book V

Brodalumab (plaque psoriasis) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Brodalumab (Plaque-Psoriasis) – Nutzenbewertung gemäß § 35a SGB V (Version 1.1; Status: 1 December 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-42 Brodalumab (...) (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-42 Version 1.1 Brodalumab (plaque psoriasis) 1 December 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Brodalumab (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 1 September 2017

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

30. Nonacog beta pegol (haemophilia B) ? Benefit assessment according to §35a Social Code Book V

Nonacog beta pegol (haemophilia B) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Nonacog beta pegol (Hämophilie B) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 26 January 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-57 (...) Nonacog beta pegol (haemophilia B) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-57 Version 1.0 Nonacog beta pegol (haemophilia B) 26 January 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nonacog beta pegol (haemophilia B) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

31. Sarilumab (rheumatoid arthritis) ? Benefit assessment according to §35a Social Code Book V

Sarilumab (rheumatoid arthritis) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Sarilumab (Rheumatoide Arthritis) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 November 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-39 (...) Sarilumab (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-39 Version 1.0 Sarilumab (rheumatoid arthritis) 13 November 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sarilumab (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

32. Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil (HIV-1 in adolescents) ? Benefit assessment according to §35a Social Code Book (SGB) V

Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil (HIV-1 in adolescents) ? Benefit assessment according to §35a Social Code Book (SGB) V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Elvitegravir/Cobistat/Emtricitabin/ Tenofovirdisoproxil (HIV-Infektion bei Jugendlichen) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 7 February 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely (...) the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-59 Elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil (HIV infection in adolescents) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-59 Version 1.0 EVG/COBI/FTC/TDF (HIV infection in adolescents) 7 February 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

33. Sofosbuvir (hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V

Sofosbuvir (hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Sofosbuvir (chronische Hepatitis C bei Jugendlichen) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 January 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A17-55 Sofosbuvir (chronic hepatitis C in adolescents) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-55 Version 1.0 Sofosbuvir (chronic hepatitis C in adolescents) 11 January 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sofosbuvir (chronic hepatitis C in adolescents) – Benefit assessment according to §35a Social Code Book V

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

34. Glecaprevir/pibrentasvir (chronic hepatitis C) ? Benefit assessment according to § 35a Social Code Book V

Glecaprevir/pibrentasvir (chronic hepatitis C) ? Benefit assessment according to § 35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Glecaprevir/Pibrentasvir (chronische Hepatitis C) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 25 October 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. 17-34 Glecaprevir/Pibrentasvir (chronic hepatitis C) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment 17-34 Version 1.0 Glecaprevir/Pibrentasvir (chronic hepatitis C) 25 October 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Glecaprevir/Pibrentasvir (chronic hepatitis C) – Benefit assessment according to §35a Social Code Book V

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

35. Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V

Bundesausschuss (Federal Joint Committee) HAQ-DI Health Assessment Questionnaire-Disability Index IQWiG Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care) MOS Medical Outcome Study MTX Methotrexate RCT randomized controlled trial SAE serious adverse event SF-36v2 Short Form (36) version 2 Health Survey SF-36v2 acute Short Form (36) version 2 Health Survey acute SGB Sozialgesetzbuch (Social Code Book) SOC System Organ Class VAS Visual analogue (...) Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.8 of the dossier assessment Tofacitinib (Rheumatoide Arthritis) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 July 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-18

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

36. Carfilzomib (multiple myeloma) ? Benefit assessment according to §35a Social Code Book V

Carfilzomib (multiple myeloma) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Carfilzomib (multiples Myelom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 November 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-38 (...) Carfilzomib (multiple myeloma) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-38 Version 1.0 Carfilzomib (multiple myeloma) 13 November 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Carfilzomib (multiple myeloma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 15 August

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

37. Dimethyl fumarate (psoriasis) - Benefit assessment according to §35a Social Code Book V

Dimethyl fumarate (psoriasis) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dimethylfumarat (Psoriasis vulgaris) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 22 December 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-49 (...) Dimethyl fumarate (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-49 Version 1.0 Dimethyl fumarate (plaque psoriasis) 22 December 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dimethyl fumarate (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

38. Daratumumab (multiple myeloma) ? Benefit assessment according to §35a Social Code Book V

Daratumumab (multiple myeloma) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Daratumumab (multiples Myelom) – Nutzen- bewertung gemäß § 35a SGB V (Version 1.0; Status: 13 November 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-40 (...) Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-40 Version 1.0 Daratumumab (multiple myeloma) 13 November 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 15 August

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

39. Ribociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V

Ribociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Ribociclib (Mammakarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 December 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-45 Ribociclib (breast (...) cancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-45 Version 1.0 Ribociclib (breast cancer) 13 December 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ribociclib (breast cancer) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 5 September 2017 Internal

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

40. Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) ? Benefit assessment according to §35a Social Code Book V

Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.9 of the dossier assessment Sofosbuvir/Velpatasvir/Voxilaprevir (chronische Hepatitis C) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 November 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. IQWiG Reports – Commission No. A17-35 Sofosbuvir/velpatasvir/ voxilaprevir (chronic hepatitis C) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-35 Version 1.0 Sofosbuvir/velpatasvir/ voxilaprevir (chronic hepatitis C) 13 November 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>